Abstract
Analysis of the most relevant studies on the pharmacological properties and molecular mechanisms of psoralidin, a bioactive compound from the seeds of Cullen corylifolium (L.) Medik. confirmed its complex therapeutic potential. In the last years, the interest of the scientific community regarding psoralidin increased, especially after the discovery of its benefits in estrogen-related diseases and as a chemopreventive agent. Growing preclinical pieces of evidence indicate that psoralidin has anticancer, antiosteoporotic, anti-inflammatory, anti-vitiligo, antibacterial, antiviral, and antidepressant-like effects. Here, we provide a comprehensive and critical review of psoralidin on its bioavailability, pharmacological activities with focus on molecular mechanisms and cell signaling pathways. In this review, we conducted literature research on the PubMed database using the following keywords: “Psoralidin” or “therapeutic effects” or “biological activity” or “Cullen corylifolium” in order to identify relevant studies regarding PSO bioavailability and mechanisms of therapeutic effects in different diseases based on preclinical, experimental studies. In the light of psoralidin beneficial actions for human health, this paper gathers complete information on its pharmacotherapeutic effects and opens new natural therapeutic perspectives in chronic diseases.
Highlights
Used since ancient times in traditional medicine, Cullen corylifolium (L.) Medik
Psoralidin is a prenylated coumestans derivative, with multiple therapeutic effects proven in preclinical studies, of which the most important and with the greatest clinical applicability as adjuvant therapies are: antiosteoporotic and anticancer
The results of our study showed that PSO could reduce the proliferation of malignant cells and stimulate apoptosis, being a potential adjunct in anticancer treatment
Summary
Used since ancient times in traditional medicine, Cullen corylifolium (L.) Medik. PSO is an orally bioavailable natural compound New pharmaceutical forms such as nanoencapsulation have been developed to increase the reduced bioavailability of PSO (Yi et al, 2008; Chen et al, 2017; Zhang et al, 2019). PSO pharmaceutical nanoformulations with chitosan and Eudragit S100 compounds have shown great potential for improving PSO bioavailability. It is still a need for further studies to improve the bioavailability of this promising compound. It is not surprising that in recent years researchers have focused on the thesaurus of medicinal plant substances and have conducted research to identify compounds that are effective in anticancer therapies (Sani et al, 2017; Salehi et al, 2019a). It has been shown to exhibit a substantial effect on inhibiting protein tyrosine phosphatase 1B, a crucial metabolite involved in insulin signaling (Ren et al, 2019)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
